V. Grygorenko, S.Volkov, R. Danylets, M. Vikarchuk, A. Valchishin

The comparative evaluation of results of prostate cancer treatment using non-steroidal antiandrogens and reduced dose

Was performed a comparative evaluation of the results of treatment with non-steroidal antiandrogen (flutamide) in 112 patients with prostate cancer stages II-IV. Study group consisted of 28 patients treated with flutamide in a reduced dose (125 mg four times/day) control group consisted of 84 patients receiving a standard dose of flutamide (250 mg three times/day). In dynamics during treatment patients in both groups showed a decreasing of the intensity of complaints, increasing of urofloumetry parameters, reducing prostate volume and PSA reduction without a significant difference in these parameters between the groups. Indicators of general and cancer-specific survival between the two groups also were not statistically different (p < 0,05). Treating with reduced dose of flutamide lowered frequency of adverse reactions, and reduced a cost of treatment.